Show simple item record

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

dc.contributor.authorVillegas, Augusto
dc.contributor.authorLee, Ki Hyeong
dc.contributor.authorCho, Byoung Chul
dc.contributor.authorPlanchard, David
dc.contributor.authorPaz-Ares, Luis
dc.contributor.authorSpigel, David R.
dc.contributor.authorWadsworth, Catherine
dc.contributor.authorTaboada, Maria
dc.contributor.authorDennis, Phillip A.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorAntonia, Scott J.
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorVansteenkiste, Johan F.
dc.contributor.authorGray, Jhanelle E.
dc.contributor.authorDaniel, Davey
dc.contributor.authorVicente, David
dc.contributor.authorMurakami, Shuji
dc.contributor.authorHui, Rina
dc.contributor.authorKurata, Takayasu
dc.contributor.authorChiappori, Alberto
dc.date.accessioned2021-03-03T10:14:12Z
dc.date.available2021-03-03T10:14:12Z
dc.date.issued2020
dc.identifier.citationGray J. E. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , Cho B. C. , et al., "Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC", JOURNAL OF THORACIC ONCOLOGY, cilt.15, sa.2, ss.288-293, 2020
dc.identifier.issn1556-0864
dc.identifier.othervv_1032021
dc.identifier.otherav_2177f527-73bb-496a-b27c-436c460b6c3a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/27542
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2019.10.002
dc.description.abstractIntroduction: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42-65, p < 0.0001) and overall survival (OS) (HR = 0.68, 95% CI: 0.53-0.87, p = 0.00251), with manageable safety and no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study.
dc.language.isoeng
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectSOLUNUM SİSTEMİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.titleThree-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
dc.typeMakale
dc.relation.journalJOURNAL OF THORACIC ONCOLOGY
dc.contributor.departmentUniversity Of Manchester , ,
dc.identifier.volume15
dc.identifier.issue2
dc.identifier.startpage288
dc.identifier.endpage293
dc.contributor.firstauthorID2277878


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record